The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Reprogramming the Tumor Microenvironment through Second‐Near‐Infrared‐Window Photothermal Genome Editing of PD‐L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy
Abstract
A photothermal genome‐editing strategy is described to improve immune checkpoint blockade (ICB) therapy by CRISPR/Cas9‐mediated disruption of PD‐L1 and mild‐hyperthermia‐induced activation of immunogenic cell death (ICD). This strategy relies on a supramolecular cationic gold nanorod that not only serves as a carrier to deliver CRISPR/Cas9 targeting PD‐L1, but also harvests the second near‐infrared‐window (NIR‐II) light and converts into mild hyperthermia to induce both ICD and gene expression of Cas9. The genomic disruption of PD‐L1 significantly augments ICB therapy by improving the conversion of dendritic cells to T cells, followed by promoting the infiltration of cytotoxic T lymphocytes into tumors, thereby reprogramming immunosuppressive tumor microenvironment into immunoactive one. Such a therapeutic modality greatly inhibits the activity of primary and metastatic tumors and exhibits long‐term immune memory effects against both rechallenged and recurrent tumors. The current therapeutic strategy for synergistic PD‐L1 disruption and ICD activation represents an appealing way for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Cited by
Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., Chai, Y., Song, J., Tang, W., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01885-2 · Cited by 258
Immunogenic Cell Death-Based Cancer Vaccines
Jin, M.-Z., & Wang, X.-P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697964 · Cited by 99
“ICD can be triggered by PDT (21), chemotherapeutic agents (18, 22–31), oncolytic viruses (OVs) (32–34) and targeted drugs (35– 38) (Table 1), as well as physical modalities such as radiation (52), hyperthermia (53), which won’t be discussed herein.”
Background
Metadata
- Authors
- Tang, H., Xu, X., Chen, Y., Xin, H., Wan, T., Li, B., Pan, H., Li, D., & Ping, Y.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2021-02-04
- Volume
- 33
- Issue
- 12
- Pages
- e2006003-e2006003
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W3127389166
- Cited by
- 203
- References
- 3
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reprogramming the Tumor Microenvironment through Second‐Near‐Infrared‐Window Photothermal Genome Editing of PD‐L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy. https://app.cochat.ai/papers/10.1002/adma.202006003
- The paper
- Tang, H., Xu, X., Chen, Y., Xin, H., Wan, T., Li, B., Pan, H., Li, D., & Ping, Y. (2021). Reprogramming the Tumor Microenvironment through Second‐Near‐Infrared‐Window Photothermal Genome Editing of PD‐L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202006003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.